Antibe Therapeutics Overview
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$161M
Antibe Therapeutics General Information
Description
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
Contact Information
Website
www.antibethera.comCorporate Office
- 15 Prince Arthur Avenue
- Toronto, Ontario M5R 1B2
- Canada
Corporate Office
- 15 Prince Arthur Avenue
- Toronto, Ontario M5R 1B2
- Canada
Antibe Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Merger/Acquisition | 17-Mar-2025 | $161M | Completed | Generating Revenue | ||
| 14. Bankruptcy: Admin/Reorg | 24-Jun-2024 | Completed | Bankruptcy: Admin/Reorg | |||
| 13. 2PO | 24-Feb-2021 | Completed | Generating Revenue | |||
| 12. PIPE | 30-Jun-2020 | Completed | Generating Revenue | |||
| 11. PIPE | 13-Aug-2019 | Completed | Generating Revenue | |||
| 10. PIPE | 27-Feb-2019 | Completed | Generating Revenue | |||
| 9. PIPE | 18-Aug-2017 | Completed | Generating Revenue | |||
| 8. PIPE | 21-Dec-2016 | Completed | Generating Revenue | |||
| 7. PIPE | 20-Jun-2016 | $1.46M | $8.84M | Completed | Generating Revenue | |
| 6. PIPE | 01-Apr-2015 | $786K | $7.38M | Completed | Generating Revenue |
Antibe Therapeutics Comparisons
Industry
Financing
Details
Antibe Therapeutics Competitors (8)
One of Antibe Therapeutics’s 8 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Surrozen | Formerly VC-backed | South San Francisco, CA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Antibe Therapeutics Patents
Antibe Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025248450-A1 | H2s-releasing mesalamine analogs | Pending | 28-May-2024 | ||
| WO-2025215470-A1 | Amorphous otenaproxesul for the treatment of acute pain | Pending | 10-Apr-2024 | ||
| EP-4791713-A1 | Polymorphic forms of otenaproxesul and compositions and uses thereof | Pending | 11-Oct-2023 | ||
| WO-2025076616-A1 | Polymorphic forms of otenaproxesul and compositions and uses thereof | Inactive | 11-Oct-2023 | ||
| EP-4784583-A1 | Phenylthione-2,3-dihydro-1h-pyrrolizine derivatives and pharmaceutical compositions thereof useful as h2s-releasing ketorolac analogues | Pending | 29-Sep-2023 | A61P29/00 |
Antibe Therapeutics Signals
Antibe Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hero Ventures | Corporation | Minority | ||
| Hero Ventures (Canada) | Venture Capital | Minority | ||
| Verdex Capital | Venture Capital | Minority |
Antibe Therapeutics Investments & Acquisitions (2)
Antibe Therapeutics’s most recent deal was a Corporate with Citagenix for . The deal was made on 02-Feb-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Citagenix | 02-Feb-2016 | Corporate | Surgical Devices | ||
| Citagenix | 16-Oct-2015 | Merger/Acquisition | Surgical Devices |
Antibe Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Antibe Therapeutics FAQs
-
Where is Antibe Therapeutics headquartered?
Antibe Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Antibe Therapeutics?
Antibe Therapeutics has 11 total employees.
-
What industry is Antibe Therapeutics in?
Antibe Therapeutics’s primary industry is Drug Discovery.
-
Is Antibe Therapeutics a private or public company?
Antibe Therapeutics is a Private company.
-
What is the current valuation of Antibe Therapeutics?
The current valuation of Antibe Therapeutics is .
-
What is Antibe Therapeutics’s current revenue?
The current revenue for Antibe Therapeutics is .
-
How much funding has Antibe Therapeutics raised over time?
Antibe Therapeutics has raised $90.8M.
-
Who are Antibe Therapeutics’s investors?
Hero Ventures, Hero Ventures (Canada), and Verdex Capital have invested in Antibe Therapeutics.
-
Who are Antibe Therapeutics’s competitors?
Mesoblast, Centrexion Therapeutics, Surrozen, Lisata Therapeutics, and Capricor Therapeutics are some of the 8 competitors of Antibe Therapeutics.
-
When was Antibe Therapeutics acquired?
Antibe Therapeutics was acquired on 17-Mar-2025.
-
Who acquired Antibe Therapeutics?
Antibe Therapeutics was acquired by Taro Pharmaceutical Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process